Skip to main content
. 2022 Feb 23;26:100776. doi: 10.1016/j.neo.2022.100776

Figure 2.

Fig 2

Proteomic and phosphoproteomic analysis of NB cells treated with selinexor. The proteomic analysis was conducted with 2 different cell lines (i.e., SH-SY5Y, KCNR) and 2 PDXs (i.e., SJNBL012407_X1 and SJNBL013762_X1). (A) The proteomics data of all PDXs and cell lines were combined for the analysis. Differentially expressed proteins at 9 hours after selinexor therapy compared to baseline are shown. Gene names in red mark p53, p53 targets, and XPO1. The light blue area marks less than 1.2-fold changes in protein expression; Student's t-test. Combined data for all four cell lines and PDXs are visualized as a volcano plot, comparing the phosphoproteomic changes at (B) 9 hours to 3 hours and (C) 9 hours to baseline. The red dot marks the peptide with site-specific phosphorylation of p53 at the S315 residue; Student's t-test. Immunoblotting of (D) cytosolic and nuclear proteins after 9-hour exposure to selinexor in SH-SY5Y and KCNR.